Monday, May 4, 2026
Lilly's CEO publicly downplaying AbbVie and Pfizer amylin programs signals the next obesity battleground is shifting from GLP-1 to amylin/combo mechanisms.
Pfizer signals continued obesity ambitions with a monthly GLP-1 candidate, keeping it in the long-acting peptide race against Lilly and Novo despite prior pipeline setbacks.
Pfizer launching a GLP-1 weight loss drug for pre-order in China signals a near-term commercial entry into the world's second-largest obesity market.
Pfizer's GLP-1 weight-loss drug (a medicine that helps people lose weight) is now available for people to pre-order in China. This is the company's first move to sell this type of drug in the Chinese market.
Pfizer's entry into China's GLP-1 weight-loss market signals renewed peptide ambitions after danuglipron setbacks, opening a competitive front against Lilly and Novo in Asia.
Speculative framing of Pfizer challenging the Lilly/Novo GLP-1 duopoly via a monthly weight-loss shot, signaling continued investor interest in less-frequent dosing as a differentiator.